FOXM1 and FOXQ1 are novel oncogenes in colorectal cancer and can be therapeutically targeted through miRNA-based therapeutics

被引：0
|
作者：
Weng, Wenhao
Okugawa, Yoshinaga
Toden, Shusuke
Goel, Ajay
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1125
引用
收藏
页数：4
相关论文
共 31 条
  • [21] Insights Into the Molecular Pathogenesis of Oesophageal Cancer Through the Identification of Novel FOXM1 Transcription Factor Target Genes Using Genome-Wide Studies.
    Wiseman, Elizabeth F.
    Han, Namshik
    Ang, Yeng S.
    Sharrocks, Andy
    GASTROENTEROLOGY, 2013, 144 (05) : S514 - S514
  • [22] MIEN1 promoter ablation provides novel evidence for colorectal cancer genome editing-based therapeutics
    Ranade, Payal
    Trivedi, Rucha
    Vishwanatha, Jamboor K.
    CANCER RESEARCH, 2023, 83 (07)
  • [23] Novel targeted therapy for advanced colorectal cancer based on transforming growth factor beta type 1 receptor genotype
    Pennison, M. J.
    Wisinski, K. B.
    Pasche, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (03) : 659 - 659
  • [24] m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop
    Bian, Yibo
    Xu, Shufen
    Gao, Zhishuang
    Ding, Jie
    Li, Chao
    Cui, Zhiwei
    Sun, Haoyu
    Li, Juan
    Pu, Juan
    Wang, Keming
    CANCER LETTERS, 2024, 596
  • [25] A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
    Landi, Nicola
    Ciaramella, Vincenza
    Ragucci, Sara
    Chambery, Angela
    Ciardiello, Fortunato
    Pedone, Paolo V.
    Troiani, Teresa
    Di Maro, Antimo
    TOXINS, 2023, 15 (01)
  • [26] A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis
    Junnan Li
    Pengchen Chen
    Qiushuang Wu
    Libin Guo
    Ka Weng Leong
    Kin Iong Chan
    Hang Fai Kwok
    Cellular and Molecular Life Sciences, 2022, 79
  • [27] A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis
    Li, Junnan
    Chen, Pengchen
    Wu, Qiushuang
    Guo, Libin
    Leong, Ka Weng
    Chan, Kin Iong
    Kwok, Hang Fai
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2022, 79 (12)
  • [28] Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics
    Mehinrad, Parnian
    Abdelfattah, Ahmed
    Sadat, Sams M. A.
    Shafaati, Tanin
    Elmenoufy, Ahmed H.
    Jay, David
    West, Frederick
    Weinfeld, Michael
    Lavasanifar, Afsaneh
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2025,
  • [29] A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation
    Xi Chen
    Xin Liu
    Qian-hui Li
    Bing-feng Lu
    Bu-min Xie
    Yu-meng Ji
    Yang Zhao
    Journal of Experimental & Clinical Cancer Research, 42
  • [30] A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation
    Chen, Xi
    Liu, Xin
    Li, Qian-hui
    Lu, Bing-feng
    Xie, Bu-min
    Ji, Yu-meng
    Zhao, Yang
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
1234